Cue Biopharma (CUE) Revenue & Revenue Breakdown
Cue Biopharma Revenue Highlights
Latest Revenue (Y)
$27.47M
Latest Revenue (Q)
$5.69M
Cue Biopharma Revenue by Period
Cue Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $27.47M | 195.75% |
| 2024-12-31 | $9.29M | 69.16% |
| 2023-12-31 | $5.49M | 340.96% |
| 2022-12-31 | $1.25M | -91.67% |
| 2021-12-31 | $14.94M | 373.68% |
| 2020-12-31 | $3.15M | -8.79% |
| 2019-12-31 | $3.46M | 202.67% |
| 2018-12-31 | $1.14M | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Cue Biopharma generated $27.47M in revenue during NA 2025, up 195.75% compared to the previous quarter, and up 870.74% compared to the same period a year ago.
Cue Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | $5.69M | -74.09% |
| 2025-12-31 | $21.94M | 921.03% |
| 2025-09-30 | $2.15M | -27.25% |
| 2025-06-30 | $2.95M | 601.66% |
| 2025-03-31 | $421.00K | -73.29% |
| 2024-12-31 | $1.58M | -52.76% |
| 2024-09-30 | $3.34M | 25.51% |
| 2024-06-30 | $2.66M | 54.80% |
| 2024-03-31 | $1.72M | -5.71% |
| 2023-12-31 | $1.82M | -13.29% |
| 2023-09-30 | $2.10M | 51.95% |
| 2023-06-30 | $1.38M | 639.04% |
| 2023-03-31 | $187.00K | 23.84% |
| 2022-12-31 | $151.00K | 122.06% |
| 2022-09-30 | $68.00K | 161.54% |
| 2022-06-30 | $26.00K | -97.40% |
| 2022-03-31 | $1.00M | -87.89% |
| 2021-12-31 | $8.25M | 244.65% |
| 2021-09-30 | $2.40M | -12.56% |
| 2021-06-30 | $2.74M | 76.37% |
| 2021-03-31 | $1.55M | 226.72% |
| 2020-12-31 | $475.32K | -32.48% |
| 2020-09-30 | $704.00K | -34.51% |
| 2020-06-30 | $1.07M | 19.44% |
| 2020-03-31 | $900.00K | -14.23% |
| 2019-12-31 | $1.05M | 6.64% |
| 2019-09-30 | $984.00K | -6.73% |
| 2019-06-30 | $1.05M | 185.14% |
| 2019-03-31 | $370.00K | 11.92% |
| 2018-12-31 | $330.60K | -26.37% |
| 2018-09-30 | $449.00K | 161.05% |
| 2018-06-30 | $172.00K | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
Cue Biopharma generated $5.69M in revenue during Q1 2026, up -74.09% compared to the previous quarter, and up 360.79% compared to the same period a year ago.
Cue Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OTLK | Outlook Therapeutics | $1.41T | $127.44B |
| IPSC | Century Therapeutics | $109.16M | - |
| CUE | Cue Biopharma | $27.47M | $5.69M |
| COEP | Coeptis Therapeutics | $1.36M | $62.87K |
| NRXP | NRx Pharmaceuticals | $1.23M | $1.07M |
| EQ | Equillium | $130.00K | - |
| SNTI | Senti Biosciences | $22.00K | - |
| BRNS | Barinthus Biotherapeutics | - | - |
| SPRB | Spruce Biosciences | - | - |
| MDCX | Medicus Pharma | - | - |
| IOBT | IO Biotech | - | - |